Inclusion Criteria:  Currently receiving sitravatinib single- agent or in combination with other therapeutic agent(s) in another Mirati- sponsored protocol Currently tolerating the treatment regimen in the parent protocol Experiencing clinical benefit with or without prior radiographic progression from the treatment regimen in the parent protocol in the opinion of the investigator and the investigator determines that continuing treatment is in the patient's best interest  Exclusion Criteria:  Known or suspected presence of other cancer Other life- threatening illness or organ system dysfunction compromising safety evaluation